

Summary of status of development and availability of A(H10) candidate vaccine viruses and potency testing reagents

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise indicated all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)

27 February 2026

Candidate vaccine viruses in preparation

Antigenic prototype	Lineage	Type	Developing Institute	Available from
A/Jiangsu/428/2021 (H10N3)	Eurasian	Reverse genetics	CDC, USA	Pending

Institute(s) and contact details for candidate vaccine virus orders and other information:

CDC: cvvrequest@cdc.gov (Subject: CVV request)

WHO CCs: <https://www.who.int/initiatives/global-influenza-surveillance-and-response-system/who-collaboration-center-erl?CxitPEOtTWx0xUd5TJdODSXcnyJqzYd7FZeivpn7xcl=>

Reference antigens (freeze-dried) (to be updated)

Parent virus	Starting Materials		Ref Ag / Lot number	Unitage (μ gHA/mL)	Available from
	CVV	Egg or Cell			

Sheep antisera (to be updated)

Purified HA from		Order Lot number	Available from
Parent virus	Egg or Cell		

WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other information:

MHRA: standards@mhra.gov.uk or enquiries@mhra.gov.uk

NIID: flu-vaccine@nih.go.jp

TGA: influenza.reagents@tga.gov.au

For reagents available from **CBER**, email CBERShippingRequests@fda.hhs.gov.

For other candidate vaccine viruses and potency testing reagents, please go to <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/zoonotic-influenza-viruses-and-candidate-vaccine-viruses>

For general enquiries, please contact gisrs-whohq@who.int